The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer
Owen, P. J., Daly, R. M., Via, J. D., Mundell, N. L., Livingston, P. M., Rantalainen, T., & Fraser, S. F. (2019). The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer. Journal of Cachexia, Sarcopenia and Muscle, 10 (5), 1036-1044. doi:10.1002/jcsm.12446
Published inJournal of Cachexia, Sarcopenia and Muscle
© 2019 The Authors Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders
Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) may prospectively decrease absolute lean mass (LM) and increase absolute fat mass (FM). Given that estimates of LM by dual‐energy X‐ray absorptiometry may be overestimated in obese people, this study examined the influence of adiposity on muscle health in men treated with ADT for PCa. Methods: This cross‐sectional study examined the influence of adiposity on total and appendicular LM (ALM), muscle cross‐sectional (CSA), and muscle strength in 70 men treated with ADT [mean (standard deviation) age, 71 (6) years] for PCa compared with age‐matched PCa (n = 52) and healthy controls (n = 70). Total body LM, FM and ALM, and 66% tibia and radius muscle CSA were quantified by dual‐energy X‐ray absorptiometry and peripheral quantitative computed tomography, respectively. ALM was further divided by height (m2) or body mass index, with muscle CSA expressed as a per cent of total limb CSA. Upper and lower body and back (three‐repetition maximum and dynamometry) muscle strength were expressed per kilogram of body weight. Results: On average, ADT‐treated men had 4.4–6.4 kg greater FM compared with controls (P ≤ 0.014) and there were no differences in total body or ALM. Total body per cent LM and ALMBMI were 3.8–5.4% (P ≤ 0.001) and 7.8–9.4% (P ≤ 0.001) lower, respectively, in ADT‐treated men compared with both controls. Percentage muscle CSA at both sites and muscle strength (except leg) were 3.0–6.0% (P ≤ 0.031) and 15–17% (P ≤ 0.010) lower, respectively, in ADT‐treated men compared with both controls. Conclusions: The findings from this study indicate muscle mass, size, and strength are compromised in men treated with ADT after accounting for their increased adiposity or body size. ...
PublisherWiley - VCH Verlag GmbH & Co. KGaA
MetadataShow full item record
- Liikuntatieteiden tiedekunta 
Showing items with similar title or keywords.
Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer patients : A secondary analysis of two randomized controlled trials Newton, Robert U.; Mavropalias, Georgios; Fragala, Maren S.; Kraemer, William J.; Häkkinen, Keijo; Taaffe, Dennis R.; Spry, Nigel; Joseph, David; Galvão, Daniel A. (Elsevier, 2021)Background Androgen deprivation therapy (ADT) contributes to lean mass loss and adiposity increases in prostate cancer patients. Radiotherapy during ADT might act synergistically and further worsen body composition. ...
Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation : A 12-month RCT Via, Jack Dalla; Owen, Patrick J.; Daly, Robin M.; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Foulkes, Stephen J.; Millar, Jeremy L.; Murphy, Declan G.; Fraser, Steve F. (Lippincott Williams & Wilkins, 2021)Purpose Androgen deprivation therapy (ADT) for prostate cancer (PCa) has multiple adverse effects on musculoskeletal health. This 12-month randomised controlled trial aimed to assess the effects of multi-component exercise ...
Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia? Owen, Patrick J.; Daly, Robin M.; Dalla Via, Jack; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Fraser, Steve F. (Springer New York LLC, 2019)Androgen deprivation therapy (ADT) for prostate cancer (PCa) can compromise muscle health. Hence, we aimed to quantify the prevalence of sarcopenia (i.e., compromised lean mass, muscle strength, and physical function) in ...
Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy Via, Jack Dalla; Daly, Robin M.; Owen, Patrick J.; Mundell, Niamh L.; Rantalainen, Timo; Fraser, Steve F. (Elsevier Inc., 2019)Androgen deprivation therapy (ADT) improves survival in men with advanced prostate cancer (PCa), but has been associated with compromised skeletal health and increased fracture risk. However, limited previous research has ...
Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy : A Systematic Review and Meta-Analysis Chen, Ziyuan; Zhang, Yuan; Lu, Chunyan; Zeng, Hao; Schumann, Moritz; Cheng, Sulin (Frontiers Media, 2019)Introduction: Androgen deprivation therapy (ADT) is considered the basic treatment for advanced prostate cancer, but it is highly associated with detrimental changes in muscle mass and muscle strength. The aim of this ...